Skip to main content
. Author manuscript; available in PMC: 2012 Oct 30.
Published in final edited form as: J Control Release. 2011 Jul 19;155(2):272–281. doi: 10.1016/j.jconrel.2011.07.018

Fig.7.

Fig.7

In vivo anti-tumor efficacy (A), Kaplan-Meier survival curve (B) and body weight changes (C) after intravenous treatment of different DOX formulations (10 mg/kg, three doses) in Raji lymphoma bearing mice (n = 5–8).